Expertise in
38
conditions

Dr. Farrukh T. Awan

Hematology | Oncology
UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center
2201 Inwood Rd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
38
conditions
UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center
2201 Inwood Rd, 
Dallas, TX 

Overview

Farrukh Awan is a Hematologist and an Oncologist practicing medicine in Dallas, Texas.

Dr. Awan is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in GA

Hospital Affiliations

UT Of Texas Southwestern University Hospital - William P. Clements Jr.

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Ut Southwestern-Bill And Rita Clements Advanced Medical Imaging Center
2201 Inwood Rd, Dallas, TX 75235
Other Locations
UT Southwestern Moncrief Cancer Center
400 W Magnolia Ave, Fort Worth, TX 76104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

An Open Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients With Lymphoid Malignancies (OPAL Study)
An Open Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients With Lymphoid Malignancies (OPAL Study)
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Biological
Study Drugs: Lisocabtagene Maraleucel, Ibrutinib
Study Phase: Phase 1/Phase 2
Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features
Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Lenalidomide, Pneumococcal Polyvalent Vaccine
Study Phase: Phase 2
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: May 12, 2026
Intervention Type: Biological, Drug
Study Drugs: Nivolumab, Varlilumab
Study Phase: Phase 2
Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Ibrutinib, Diptheria Toxoid, Tetanus Toxoid, Acellular Pertussis Vaccine, Pneumococcal 13-Valent Conjugate Vaccine, Influenza Trivalent Vaccine
Study Phase: Phase 2
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
View 9 Less Clinical Trials

144 Total Publications

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal: Journal for immunotherapy of cancer
Published: June 10, 2026
Similar Doctors
Expertise in
33
conditions
Dr. Daniel C. Bowers
Hematology | Oncology
Expertise in
33
conditions
Dr. Daniel C. Bowers
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (0.8 miles away)
214-456-2382
Languages Spoken:
English
See accepted insurances

Daniel Bowers is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Bowers is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Ependymoma, Posterior Fossa Tumor, Medulloblastoma, and Brain Tumor.

Expertise in
11
conditions
Dr. Naomi J. Winick
Hematology | Oncology
Expertise in
11
conditions
Dr. Naomi J. Winick
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (0.8 miles away)
214-648-3896
Languages Spoken:
English
See accepted insurances

Naomi Winick is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Winick is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Febrile Neutropenia, Childhood Acute Myeloid Leukemia, and Bone Marrow Transplant.

Expertise in
10
conditions
Dr. Alecia C. Nero
Hematology | Oncology
Expertise in
10
conditions
Dr. Alecia C. Nero
Hematology | Oncology
Referral may be required

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (0.6 miles away)
214-648-4180
Languages Spoken:
English
See accepted insurances

Alecia Nero is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Nero is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Farrukh T. Awan

How do I make an appointment with Dr. Farrukh T. Awan?

You can book an appointment with Dr. Farrukh T. Awan by calling their office at 214-645-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Farrukh T. Awan a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Farrukh T. Awan is classified as an Elite expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Farrukh T. Awan specialize in?

While Dr. Farrukh T. Awan is a Hematology, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Small Lymphocytic Lymphoma (SLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Farrukh T. Awan participate in research or clinical trials?

Yes. Dr. Farrukh T. Awan has published 144 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Farrukh T. Awan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Farrukh T. Awan accept my insurance?

Dr. Farrukh T. Awan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 214-645-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Awan's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 23 Advanced Conditions
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile